127 patents currently held
29 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
24
Ending by 2030
Nov 2026
Next term end
99
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2039 · High confidence
Also notable
Ends Apr 2029 · High confidence
Also notable
Ends Apr 2032 · High confidence
Systems and Methods for Control System Security
US 10,896,261
Cited by 47 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
Sphingosine Kinase Type 1 Inhibitors, Compositions and Processes for Using Same
US 8,372,888
Cited by 35 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Sulfated Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Proliferation
US 9,034,859
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Feb 2039 · High confidence
Cited by 25 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2039.
now held by Biocircuit Technologies, Inc.
Also notable
Ends Apr 2029 · High confidence
The most cited patent in this portfolio, cited by 60 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2029.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Nov 23 to 30, 2026 · next Nov 23
- 3 fees due Dec 6 to 13, 2026 · next Dec 6
- 2 fees due Jan 4 to 9, 2027 · next Jan 4
- 1 fee due Feb 28, 2027The maintenance fee for Sphingosine Kinase Type 1 Inhibitors and Uses Thereof (US 11,737,992) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Method for One-Step Synthesis, Cross-Linking and Drying of Aerogels (US 10,414,894) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 3 fees due Apr 1 to 29, 2027 · next Apr 1
- 1 fee due May 14, 2027The maintenance fee for Nitric Oxide-Releasing 3D-PRINTING Compositions and Uses Thereof (US 11,814,519) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Aug 6 to 13, 2027 · next Aug 6
- 4 fees due Sep 1 to 24, 2027 · next Sep 1
- 1 fee due Oct 21, 2027The maintenance fee for Sphingosine Kinase Type 1 Inhibitors and Uses Thereof (US 10,624,863) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
- 1 fee due Nov 17, 2027The maintenance fee for Assessment and Prediction of Cardiovascular Status During Cardiac Arrest and the Post-Resuscitation Period Using Signal Processing and Machine Learning (US 9,339,241) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 20, 2026
- 6 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 99 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Sphingosine Kinase Type 1 Inhibitors, Compositions and Processes for Using Same | 7 in force | to Apr 2029 |
| Induction of Tumor Hypoxia for Cancer Therapy | 4 in force | to Sep 2029 |
| Method for One-Step Synthesis, Cross-Linking and Drying of Aerogels | 3 in force | to Mar 2036 |
| Organ Protection Solution and Method of Use | 3 in force | to Dec 2032 |
| Prevention of Ventilator Associated Pneumonia (VAP) | 3 in force | to Jul 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,376,472 | Polyvalent Chimeric Ospc Vaccinogen and Diagnostic Antigen In force · Low confidence | In force | Low confidence | |
| US 10,751,494 | Prevention of Ventilator Associated Pneumonia (VAP) In force · Medium confidence | In force | Medium confidence | |
| US 7,668,357 | Method and System for Using Computed Tomography to Test Pulmonary Function In force · High confidence | In force | High confidence | |
| US 9,457,163 | Prevention of Ventilator Associated Pneumonia (VAP) In force · High confidence | In force | High confidence | |
| US 8,042,544 | Prevention of Ventilator Associated Pneumonia (VAP) In force · High confidence | In force | High confidence | |
| US 8,609,360 | Method for Diagnosing Acute Ischemic Events in Human Subjects In force · High confidence | In force | High confidence | |
| US 7,781,580 | Stilbene Derivatives as New Cancer Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 8,591,921 | Induction of Tumor Hypoxia for Cancer Therapy In force · High confidence | In force | High confidence | |
| US 10,159,676 | Induction of Tumor Hypoxia for Cancer Therapy In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 10,426,779 | Induction of Tumor Hypoxia for Cancer Therapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 127: 29 patents in force now held by others · 156 patents ended · 101 applications pending · 171 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.